Plain-English translation of NCT07492628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses immune cells from donated cord blood that have been engineered in the lab to recognize and attack bladder cancer cells. The medication is given as an infusion into your bloodstream, after you receive chemotherapy drugs to prepare your body. This approach is designed for people whose cancer has progressed despite previous treatments like chemotherapy or immunotherapy.
Advanced bladder cancer is very difficult to treat once it stops responding to standard therapies, and many patients have limited options left. This trial exists to see whether this medication—which combines two different targeting strategies and uses a type of immune cell called NK cells—can be more effective and safe for people in this situation.
You likely qualify if…
You likely don't qualify if…
You will first receive two chemotherapy drugs ( and ) to prepare your immune system. Then you will receive two infusions of the engineered immune cells, given 7 days apart, as the start of a 21-day treatment cycle. You will have close monitoring with blood tests, imaging scans, and visits to check for side effects. The trial has two parts: the first part tests different dose levels to find the safest dose, and the second part enrolls more patients at that chosen dose to confirm safety and see how well it works.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China